Calton & Associates’s Prothena Corp PRTA Stock Holding History

Calton & Associates’s Portfolio PRTA Stock Details PRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7	Closed	–	–	1040
2017 Q4	$0	Buy	+7	New	+$356	﹤0.01%	1508

Other funds holding PRTA

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calton & Associates's PRTA Position: Q1 2018 in Review

Calton & Associates sold out of Prothena Corp (PRTA) in Q1 2018, closing a stake of 7 shares.

Calton & Associates first reported a position in PRTA in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 142 funds tracked by Wall St. Rank hold PRTA as of Q1 2018.

Calton & Associates reported no remaining Prothena Corp position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 7 Prothena Corp shares in Q1 2018.
Calton & Associates first reported a position in Prothena Corp in Q4 2017 and held it in 1 quarter.
Calton & Associates's Prothena Corp position peaked at $0 in Q4 2017.
142 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.